Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.

4 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2010.

30 Mar 2011

Longer Looks: Behind the hospital money curtain; Medical data breaches

Think you would stick to a diet if someone paid you for it? Would you be more likely to exercise if you were fined each time you bailed on your scheduled workout? Research in recent years suggests—and a handful of new businesses are betting—that you might.

25 Mar 2011

Philanthropists triple-match public's donations for TGen's unTEAL cure ovarian cancer event

Philanthropists Foster and Lynn Friess will triple-match the public's donations - up to a total of $100,000 - for TGen's 2nd annual unTEAL a cure ovarian cancer event.

21 Mar 2011

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer.

21 Mar 2011

Celebrity Chefs Cook Gala to support cancer research at UC San Diego

Top celebrity chefs from around the country will gather in San Diego April 16 for the 30th Celebrity Chefs Cook Gala benefiting research at the UC San Diego Moores Cancer Center. Themed "Epicurean Elegance: Food for the Mind, Body and Spirit," the gala will feature lush food artistry as 11 premiere chefs prepare their signature hors d'oeuvres paired with fine wine. Proceeds from the event will support the cancer center's most urgent needs.

19 Mar 2011

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.

17 Mar 2011

Scientist suggests breaking tangled mucus barrier can help treat cancer

Measuring the mechanical strength of cancer cell mucus layers provides clues about better ways to treat cancer, and also suggests why some cancer cells are more resistant to drugs than others, according to Kai-tak Wan, associate professor of engineering at Northeastern University, Boston, Mass.

17 Mar 2011

Updated NCCN Guidelines for Ovarian Cancer outline new treatment options for women

Although finding effective screening tools remains a priority, new treatment options for women with ovarian cancer, such as the ones outlined in the updated NCCN Guidelines for Ovarian Cancer, are vital to making steady progress against the disease according to Robert J. Morgan, MD, of City of Hope Comprehensive Cancer Center and chair of the NCCN Guidelines Panel for Ovarian Cancer.

16 Mar 2011

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the 12 months ended December 31, 2010, and provided a business update.

11 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO

Vermillion, a molecular diagnostics company, today announced the presentation of positive preliminary data from its collaboration with Johns Hopkins University School of Medicine to identify biomarkers that improve on the specificity of CA125 for the identification of malignant ovarian tumors.

9 Mar 2011

MabCure presents ovarian cancer diagnostic blood test study results at SGO meeting

Biotechnology company MabCure, Inc. is presenting the results of its recently completed study on the diagnosis of ovarian cancer utilizing its proprietary monoclonal antibodies at the annual meeting of the Society of Gynecological Oncologists.

9 Mar 2011

Overall survival rate for ovarian cancer have increased over last 30 years

Survival from ovarian cancer has almost doubled over the last 30 years according to new figures from Cancer Research UK released today.

9 Mar 2011

Caris Life Sciences to highlight new approaches for gynecologic cancers at SGO 2011 conference

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, today announced highlights from the company's upcoming symposium, "Using Biomarker Expression to Guide Therapy: An Evidence-Based Approach for Gynecologic Cancers," at the Society of Gynecologic Oncologists 2011 Annual Meeting on Women's Cancer in Orlando, FL on March 6.

5 Mar 2011

Study reports highest rate of exclusive breastfeeding in El Camino Women's Hospital

The Women's Hospital at El Camino Hospital had the highest rate of exclusive and partial breastfeeding by new mothers of any hospital in the state for 2009, according to a study recently released by the UC-Davis Human Lactation Center and the California WIC Association.

5 Mar 2011

Scientist receives $4 million Australia fellowship to continue cancer origin research

Walter and Eliza Hall Institute cancer researcher Professor Jane Visvader has received a $4 million fellowship from the Australian Government to continue her work into the origin of breast, ovarian and lung cancers.

3 Mar 2011

Genetics and cancer research

The 20th century was dominated by breakthroughs in physics and chemistry, but the 21st century will belong to genetics and biotechnology. Cancer research is just one area among many that is being transformed by the sequencing of the human genome. This was one of the topics discussed in our recent panel with leading cancer researchers, part of our Breakthroughs: Cancer series.

3 Mar 2011

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

EntreMed fourth quarter revenue is $3.7 million for fiscal year 2010

Longer Looks: Behind the hospital money curtain; Medical data breaches

Philanthropists triple-match public's donations for TGen's unTEAL cure ovarian cancer event

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

Celebrity Chefs Cook Gala to support cancer research at UC San Diego

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

Scientist suggests breaking tangled mucus barrier can help treat cancer

Updated NCCN Guidelines for Ovarian Cancer outline new treatment options for women

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO

MabCure presents ovarian cancer diagnostic blood test study results at SGO meeting

Overall survival rate for ovarian cancer have increased over last 30 years

Caris Life Sciences to highlight new approaches for gynecologic cancers at SGO 2011 conference

Study reports highest rate of exclusive breastfeeding in El Camino Women's Hospital

Scientist receives $4 million Australia fellowship to continue cancer origin research

Genetics and cancer research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in